openPR Logo
Press release

c-MET / HGF Inhibitors Market to Register Steady Growth During 2017- 2025

01-16-2018 01:09 PM CET | Health & Medicine

Press release from: Persistence Market Research

c-MET / HGF Inhibitors Market to Register Steady Growth During

c-Met is a proto-oncogene responsible for encoding the high-affinity receptor for hepatocyte growth factor (HGF). Hepatocyte growth factor is also known as scatter factor which participates in HGF/c-MET signaling pathway. This pathway plays vital role in mitogenesis and morphogenesis during embryonic development and wound healing. The controlled natural activity of c-Met and HGF is important in mammalian development, tissue maintenance, and repair. Binding of HGF to c-MET receptor induces several biological responses collectively known as invasive growth program. These responses are elicited due to activation of several pathways such as RAS pathway, PI3K pathway, STAT pathway, beta-catenin pathway and Notch pathway. However, dysregulation of the HGF/c-MET signaling pathway has been associated with the progression of cancers through activation of oncogenic pathways, angiogenesis and metastasis.

Request for Table of Contents @ https://www.persistencemarketresearch.com/toc/21535

c-Met kinase represents a novel target for cancer therapy and several research institutes and pharmaceuticals companies are engaged in developing new oncology drugs based on this inhibition of HGF or c-Met-dependent signaling pathway. Number of approaches being attempted to target c-Met include: c-Met biologic inhibitors, small molecule c-Met inhibitors, HGF antagonist antibodies, c-Met antagonist antibodies (MetMAb) and HGF kringle variant antagonists. A study undertaken by University of Heidelberg, Heidelberg, Germany demonstrated therapeutic potential of cabozantinib (Exelixis, Inc., Phase III) for against pancreatic ductal adenocarcinoma (PDA) and this molecule induced low-level of resistance compared to gemcitabine.

The major cancers such as breast, colon and non-small-cell lung carcinoma (NSCLC) are being examined for efficacy with c-MET / HGF inhibitors. Several small molecule c-Met kinase inhibitors have demonstrated clinical efficacy in cancer treatment and many clinical trials are underway. However, as the small molecule inhibitors lack specificity or selectivity they can cause toxicity. Therefore, researchers are increasing focus to develop antibody therapeutics against c-Met or HGF. Several drugs are in developmental stage and underway clinical trials in various phases of clinical trials. Some of the prominent molecules include ARQ 197 (Arcule, Inc., Phase II), AV-299 (AVEO Pharmaceuticals, Inc., Phase II), cabozantinib (Exelixis, Inc., Phase III), JNJ-38877605 (Johnson & Johnson), PF04217903 (Pfizer, Inc., Phase I), PF02341066 (Pfizer, Inc., Phase II), GSK1363089 (GlaxoSmithKline plc), MK-2461 (Merck & Co., Phase II), MP470 (SuperGen, Inc., Phase I), and MGCD265 (Methylgene, Inc., Phase I), AMG102 (Amgen, Inc., Phase II), HuL2G7 (Galaxy Biotech, LLC) and MetMAb (Genentech, Inc., Phase I).

The global c-MET / HGF inhibitors market is yet to establish and hence every company is trying to expedite the research and development activity along with clinical trials. The larger multinationals are collaborating with companies having intellectual property rights but suffer from an insufficient capacity to commercialize the molecules. For instance, AstraZeneca signed a licensing deal with Hutchison MediPharma Ltd., to develop volitinib (HMPL-504/AZD6094) in non-small-cell lung carcinoma (NSCLC). Another recent development in the market was AVEO Oncology entering into a worldwide agreement with Biodexis in which latter company’s companion diagnostic test will be commercialized with AVEO’s ficlatuzumab (HGF inhibitory antibody).

Request to View Sample of Research Report @ https://www.persistencemarketresearch.com/samples/21535

Some of the companies having presence in the global c-MET / HGF inhibitors market are Abxign, Inc., Abbott Laboratories, Amgen, Inc., ArQule, Inc., Astex Therapeutics Ltd., AVEO Pharmaceuticals, Inc., Bristol-Myers Squibb (BMS) Co., Chroma Therapeutics Ltd., Daiichi Sankyo Co. Ltd., Deciphera Pharmaceuticals, LLC, Eisai Co., Ltd., Eli Lilly and Co., Exelixis, Inc., Genmab A/S, Galaxy Biotech, LLC, GlaxoSmithKline (GSK) plc, Hutchison MediPharma Ltd., Johnson & Johnson, Kringle Pharmaceuticals, Inc., Merck & Co., Methylgene, Inc., Novartis AG, Pfizer, Inc., ProMetic BioTherapeutics, Inc., and Takeda Pharmaceutical Co.

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us

Persistence Market Research

305 Broadway

7th Floor, New York City,

NY 10007, United States,

Telephone - +1-646-568-7751

USA – Canada Toll Free: 800-961-0353

Email: sales@persistencemarketresearch.com

Web: http://www.persistencemarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release c-MET / HGF Inhibitors Market to Register Steady Growth During 2017- 2025 here

News-ID: 902339 • Views: 238

More Releases from Persistence Market Research

The Latex Agglutination Test market to invigorate from 2019 to 2029
The reaction between a specific antibody and antigen results in visible clumping is called agglutination. The test used to analyze the variation on the clumping ability of the antigen when it reacted with an antibody placed on the surface of latex particles is called latex agglutination test. The agglutination reaction may also be reversed, the use of systematic beads provide the advantages and consistency, uniformity, and stability. Moreover, the latex
The Hormone Biosimilars market to witness explicit growth from 2019 and 2029
Growth hormone deficiency causes when pituitary gland does not produce the desired amount of the growth hormones. There are various disorders related to lack of growth hormones in the adults as well as children. Growth hormone deficiency is rare disorder and it can be present from the birth, genetic mutations, trauma, exposure to certain radiations, infection and tumor growth inside the brain. The incidence of the growth hormone deficiency is
Global Battery Operated Smoke Detectors Market to Undergo Rapid Advancements Dur …
The Global Battery Operated Smoke Detectors Market report scrutinizes the market behavior and the manner in which the market has been performing and responding to various situations. Alongwith the usual market taxonomy, the report encloses growth rate comparison, current and future lookout, and year-on-year progress. All of the market insights are presented in terms of volume (x units) and value (Mn/Bn USD). A broad visional evaluation from every critical perspective of
Piling Equipment And Supplies Market Unit Sales to Witness Heightened Growth wit …
The global Piling Equipment And Supplies Market report scrutinizes the market behavior and the manner in which the market has been performing and responding to various situations. Alongwith the usual market taxonomy, the report encloses growth rate comparison, current and future lookout, and year-on-year progress. All of the market insights are presented in terms of volume (x units) and value (Mn/Bn USD). A broad visional evaluation from every critical perspective of

All 5 Releases


More Releases for HGF

Hepatocyte Growth Factor (HGF) Inhibitor Therapeutics - Pipeline Analysis 2019 | …
Hepatocyte growth factor (HGF) is secreted by human pancreatic stellate cells and present predominantly on cancer cells. Thus, HGF inhibitors has emerged as an effective therapy in preventing local tumor growth. Also, studies have demonstrated that HGF inhibitors are significantly more effective than Gemcitabine in inhibiting tumor angiogenesis and metastasis. Download the sample report @ https://www.pharmaproff.com/request-sample/1201 Studies have demonstrated that the HGF inhibitor can be a novel therapeutics that can be developed
c-MET/HGF Inhibitors Market Production and CAGR (%) Comparison by Types
c-Met is a proto-oncogene responsible for encoding the high-affinity receptor for hepatocyte growth factor (HGF). Hepatocyte growth factor is also known as scatter factor which participates in HGF/c-MET signaling pathway. This pathway plays vital role in mitogenesis and morphogenesis during embryonic development and wound healing. The controlled natural activity of c-Met and HGF is important in mammalian development, tissue maintenance, and repair. Binding of HGF to c-MET receptor induces several
C-MET / HGF Inhibitors Global Market 2019 Top Key Players – Abxign,  Abbott L …
Global C-MET / HGF Inhibitors Market WiseGuyRerports.com Presents Global C-MET / HGF Inhibitors Market Insights, Forecast to 2025” New Document to its Studies Database. The Report Contain 148 Pages With Detailed Analysis. Description c-Met is a proto-oncogene responsible for encoding the high-affinity receptor for hepatocyte growth factor (HGF). Hepatocyte growth factor is also known as scatter factor which participates in HGF/c-MET signaling pathway. This pathway plays vital role in mitogenesis and morphogenesis during
c-MET / HGF Inhibitors Market to Record an Exponential CAGR by 2025
c-Met is a proto-oncogene responsible for encoding the high-affinity receptor for hepatocyte growth factor (HGF). Hepatocyte growth factor is also known as scatter factor which participates in HGF/c-MET signaling pathway. This pathway plays vital role in mitogenesis and morphogenesis during embryonic development and wound healing. The controlled natural activity of c-Met and HGF is important in mammalian development, tissue maintenance, and repair. Binding of HGF to c-MET receptor induces several
C Met Hgf Inhibitors Market Set to Witness an Uptick During 2017 - 2025
c-Met is a proto-oncogene responsible for encoding the high-affinity receptor for hepatocyte growth factor (HGF). Hepatocyte growth factor is also known as scatter factor which participates in HGF/c-MET signaling pathway. This pathway plays vital role in mitogenesis and morphogenesis during embryonic development and wound healing. The controlled natural activity of c-Met and HGF is important in mammalian development, tissue maintenance, and repair. Binding of HGF to c-MET receptor induces several
HGF Family Day Empowers Florida Families with Children with Growth Disorders
Human Growth Foundation will host “HGF Family Day” on Saturday, September 24, 2016, at Sea World, from 9:00 am – 6:00 pm, in Orlando, Florida. The nonprofit event is in celebration of National Growth Awareness Week and will engage, educate and empower local families whose children have growth disorders. HGF Family Day will include workshops to learn about the latest developments in growth disorders, combating bullying, and obtaining medical insurance